Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure

Core Insights - The TEAM-HF trial aims to improve clinical outcomes for patients with worsening heart failure by establishing new criteria to identify those at high risk for end-stage heart failure and offering advanced therapies sooner [1][3][5] Group 1: Clinical Trial Overview - The TEAM-HF trial will enroll up to 850 patients across 75 sites globally, utilizing Abbott's CardioMEMS™ HF System to measure pulmonary artery pressures (PAP) [1][5] - The trial seeks to provide timely access to life-saving HeartMate 3™ left ventricular assist devices (LVADs) for patients identified as high-risk [1][3] Group 2: Heart Failure Statistics - Approximately 6.7 million people in the U.S. currently have heart failure, with projections to rise to 8.5 million by 2030 [2] - Patients dependent on IV-administered heart failure medications have a median survival of only nine months, highlighting the urgency for earlier intervention [4] Group 3: Innovative Approach - The trial will utilize objective measures from the CardioMEMS sensor to assess heart failure progression and determine the appropriate timing for LVAD implementation [5][6] - Patients whose PAP levels do not decrease with medical therapy will be randomized to receive either the HeartMate 3 LVAD or continue with their current medications [5] Group 4: Expected Outcomes - The anticipated results of the TEAM-HF study aim to improve survival rates and quality of life for heart failure patients by facilitating quicker access to advanced therapies [6] - The trial's primary and secondary endpoints will be evaluated at two years, with long-term follow-up extending to five years [6]